What tirzepatide actually is
Tirzepatide is a once-weekly subcutaneous injectable that activates two hormone receptors involved in metabolism: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones are naturally produced by your gut in response to eating.
Their normal jobs:
- Stimulate insulin release when blood sugar rises
- Slow gastric emptying (food stays in the stomach longer, prolonging satiety)
- Signal the brain's satiety centres (you feel full sooner and stay full longer)
- Modulate fat metabolism
Tirzepatide is a dual agonist that activates both receptors continuously at therapeutic levels. The cumulative effect: reduced appetite, prolonged satiety, improved insulin sensitivity, and gradual weight loss over months.
What the clinical evidence shows
The SURMOUNT trials (the pivotal Phase 3 studies for tirzepatide in obesity) reported:
- Average 15% body weight reduction at 5mg weekly dose over 72 weeks
- Average 19.5% body weight reduction at 10mg dose
- Average 20.9% body weight reduction at 15mg dose (highest evaluated)
- Improvements in HbA1c, lipid profile, blood pressure
- Reduction in waist circumference proportional to weight loss
These results combine medication with lifestyle intervention (diet, activity). Medication alone, without behavioural change, produces meaningfully less effect.
Who qualifies for a medical weight management programme
Tirzepatide is appropriate for adults who meet at least one of:
- BMI ≥ 30 (obesity)
- BMI ≥ 27 (overweight) plus at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea)
- Pre-existing type 2 diabetes with HbA1c above target on metformin alone
For Singapore's typical patient population, BMI categories are interpreted using Asian-adjusted cutoffs (overweight ≥ 23, obese ≥ 27.5) per MOH guidance — so the BMI 27+ threshold corresponds to clinically meaningful overweight in our population.
Who shouldn't take it
Tirzepatide is contraindicated in:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or breastfeeding
- Pre-existing severe gastroparesis
- History of pancreatitis (relative; case-by-case assessment)
- Type 1 diabetes (not indicated; risk of ketoacidosis without insulin)
Pre-treatment screening includes thyroid history, abdominal symptoms history, and baseline blood work (HbA1c, lipid panel, liver function, lipase).
What a programme actually looks like
Initial consultation (60 minutes)
Comprehensive medical assessment: weight history, eating patterns, activity, sleep, medications, family history. Baseline blood work. BMI and body composition measurement. Goal-setting discussion. If suitable, the programme begins.
Dose titration (Weeks 1-16)
Tirzepatide is started at the lowest dose (2.5mg weekly) for 4 weeks. Dose increases by 2.5mg every 4 weeks based on tolerance and response. Most patients reach 10mg or 15mg by week 16, though some plateau earlier with adequate weight loss.
Maintenance phase (Months 4-12)
Once the optimal dose is reached, the patient continues weekly self-injection. Doctor reviews every 4 to 8 weeks. Blood work every 3 to 6 months.
Long-term plan (Year 2+)
For sustained weight loss, the medication is typically continued long-term. Some patients can taper to lower maintenance doses; others continue at full dose. Stopping without sustained behavioural change typically results in regain over 6 to 12 months.
What the side effects are like
Most common (50%+ of patients during titration):
- Nausea, particularly after meals containing fat
- Reduced appetite (this is the therapeutic effect)
- Mild constipation or loose stools
- Occasional vomiting, particularly with eating beyond the new satiety threshold
These side effects are typically worst in the first 2-4 weeks after each dose increase, then settle. Slower titration helps. Many patients describe the eating pattern as "needing to learn to listen to fullness again."
Less common but important:
- Acute gallbladder issues (rapid weight loss is a known gallstone risk)
- Pancreatitis (rare; new abdominal pain should prompt immediate review)
- Hair shedding during rapid weight loss (transient)
- "Ozempic face" — perceived facial gauntness from fat loss in cheeks and temples
The "Ozempic face" question
Patients losing significant weight quickly often notice facial volume loss alongside body fat loss — particularly in the temples, cheeks, and undereye areas. This isn't a medication-specific side effect; it's a consequence of rapid weight loss generally. Patients who plan ahead can address this concurrently with:
- Collagen-stimulating injections (Sculptra) for structural restoration
- Bio-remodellers (Profhilo) for skin quality
- Non-surgical lifting (HIFU, RF microneedling) for skin laxity in newly-thinner areas
This integration is one of the reasons medical aesthetic clinics are well-placed to run weight management programmes — the body-and-face aspects are addressed together.
The economics — honest framing
Tirzepatide programmes in Singapore are not cheap. Monthly medication cost varies significantly with dose, plus consultation and review fees. For most patients, the meaningful comparison isn't medication cost vs. diet alone — it's medication cost vs. the long-term healthcare cost of untreated obesity (type 2 diabetes management, cardiovascular events, joint replacement, sleep apnoea CPAP).
Our pricing methodology is explained in detail on the How We Price page.
What to do next
The right next step is a structured initial consultation to determine whether you're a candidate, what dose would be appropriate, and what realistic outcomes look like over 12 to 24 months. This is medical care, not aesthetic treatment, so the assessment is thorough.